SEARCH

SEARCH BY CITATION

References

  • Alessi, M.C. & Juhan-Vague, I. (2006) PAI-1 and the metabolic syndrome: links, causes, and consequences. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 22002207.
  • Booth, N.A. (1999) Fibrinolysis and thrombosis. Baillieres Best Practice Research Clinical Haematology, 12, 423433.
  • Catena, C., Novello, M., Lapenna, R., Baroselli, S., Colussi, G., Nadalini, E., Favret, G., Cavarape, A., Soardo, G. & Sechi, L.A. (2005) New risk factors for atherosclerosis in hypertension: focus on the prothrombotic state and lipoprotein(a). Journal of Hypertension, 23, 16171631.
  • Dormandy, J.A. & Rutherford, R.B. (2000) Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). Journal of Vascular Surgery, 31, S1S296.
  • Feinbloom, D. & Bauer, K.A. (2005) Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arteriosclerosis, Thrombosis, and Vascular Biology, 25, 20432053.
  • Ladenvall, C., Gils, A., Jood, K., Blomstrand, C., Declerck, P.J. & Jern, C. (2007) Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 955962.
  • Leebeek, F.W., Goor, M.P., Guimaraes, A.H., Brouwers, G.J., Maat, M.P., Dippel, D.W. & Rijken, D.C. (2005) High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. Journal of Thrombosis Haemostasis, 3, 22112218.
  • Lijfering, W.M., Veeger, N.J., Brouwer, J.L. & Van Der Meer, J. (2007) The risk of venous and arterial thrombosis in hyperhomocysteinemic subjects may be a result of elevated factor VIII levels. Haematologica, 92, 17031706.
  • Lisman, T., Leebeek, F.W., Mosnier, L.O., Bouma, B.N., Meijers, J.C., Janssen, H.L., Nieuwenhuis, H.K. & De Groot, P.G. (2001) Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology, 121, 131139.
  • Lisman, T., De Groot, P.G., Meijers, J.C. & Rosendaal, F.R. (2005) Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood, 105, 11021105.
  • MacCallum, P.K. & Meade, T.W. (1999) Haemostatic function, arterial disease and the prevention of arterial thrombosis. Baillieres Best Practice Research Clinical Haematology, 12, 577599.
  • Meade, T.W., Ruddock, V., Stirling, Y., Chakrabarti, R. & Miller, G.J. (1993) Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet, 342, 10761079.
  • Meltzer, M.E., Doggen, C.J., De Groot, P.G., Rosendaal, F.R. & Lisman, T. (2007) Fibrinolysis and the risk of venous and arterial thrombosis. Current Opinion in Hematology, 14, 242248.
  • Munkvad, S., Gram, J. & Jespersen, J. (1990) A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. European Heart Journal, 11, 525528.
  • Pasternak, R.C., Grundy, S.M., Levy, D. & Thompson, P.D. (1996) 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 3. Spectrum of risk factors for coronary heart disease. Journal of the American College of Cardiology, 27, 978990.
  • Prins, M.H. & Hirsh, J. (1991) A critical review of the relationship between impaired fibrinolysis and myocardial infarction. American Heart Journal, 122, 545551.
  • Rosendaal, F.R. (1999) Venous thrombosis: a multicausal disease. Lancet, 353, 11671173.
  • Smith, A., Patterson, C., Yarnell, J., Rumley, A., Ben-Shlomo, Y. & Lowe, G. (2005) Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation, 112, 30803087.
  • The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal of the American Medical Association, 285, 24862497.
  • Wilhelmsen, L., Svardsudd, K., Korsan-Bengtsen, K., Larsson, B., Welin, L. & Tibblin, G. (1984) Fibrinogen as a risk factor for stroke and myocardial infarction. New England Journal of Medicine, 311, 501505.
  • Ye, Z., Liu, E.H., Higgins, J.P., Keavney, B.D., Lowe, G.D., Collins, R. & Danesh, J. (2006) Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet, 367, 651658.
  • Zorio, E., Castello, R., Falco, C., Espana, F., Osa, A., Almenar, L., Aznar, J. & Estelles, A. (2003) Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. British Journal of Haematology, 122, 958965.